Inhibikase Therapeutics Reports Results from Phase 2 201 Trial for Risvodetinib
On January 29, 2025, Inhibikase Therapeutics, Inc. (NYSE:IKT) disclosed findings from the Phase 2 201 trial (the “201 Trial”) evaluating risvodetinib, a selective inhibitor of non-receptor Abelson Tyrosine Kinases, in untreated Parkinson’s disease. The 201 Trial involved 126 individuals with untreated Parkinson’s disease who were, on average, 14 months post-diagnosis. Participants received doses of 50 […]
More Stories
Wall Street Slides on Opening Bell as Oil Surges Past $100 Amid Iran War Jitters
By Tom Ozimek Wall Street’s main indexes opened in the red on March 9 as investors reacted to a surge...
Is Untamed Season 2 Released? Know about the Release Date and Cast
Netflix’s American crime drama television series, Untamed, got a lot of praise after its debut in 2025. It topped the...
Saudi Arabia Warns Iran It Will Be ‘The Greatest Loser’ If It Escalates Attacks
By Jack Phillips Saudi Arabia issued a fresh warning to Iran on Monday following an Iranian attack that killed two...
USPS Could Run Out of Funds in 1 Year Without Congressional Action: Postmaster General
By Kimberly Hayek U.S. Postal Service Postmaster General David Steiner said on March 4 that the service could run out...
MobLand Season 2: Release Date, Cast, Trailer, and Expected Plot
Since the debut of the crime drama MobLand, it has become one of the most talked-about 10-episode series. With its...
100 Percent of Audited Medicaid Claims for Autism Care in Colorado Were Improper or Flawed: Report
By Sylvia Xu Colorado’s Medicaid program made an estimated $77.8 million in improper payments and another $207.4 million in potentially...